Literature DB >> 14724671

Cationic corticosteroid for nonviral gene delivery.

J A Gruneich1, A Price, J Zhu, S L Diamond.   

Abstract

Delivery of plasmid DNA for gene therapy often provokes an inflammatory response that reduces transgene expression. Cationic lipids for lipofection lack pharmacological activity despite the hydrophobicity of many drug candidates that could be exploited. We report a one-step synthesis of a water-soluble, dexamethasone-spermine (DS) cationic lipid that has potent gene transfer capability in confluent endothelial cells when used with the neutral lipid, dioleoylphosphatidylethanolamine (DOPE). In contrast, unconjugated mixtures of dexamethasone, spermine, and/or DOPE have essentially no gene transfer activity. DS retains partial corticosteroid character as quantified by the rapid translocation of glucocorticoid receptor to the nucleus and by dose-dependent transactivation from a glucocorticoid response element. DS has anti-inflammatory activity in vivo in the mouse thioglycollate model of inflammation. In a mouse lung model, DS:DOPE resulted in significantly less interferon-gamma production at Day 1 and elevated transgene expression at Days 1 and 7 postintranasal instillation compared to DC-Chol:DOPE (sterol:DOPE:phosphate molar ratio of 1:1:1). Cationic pharmacophores such as DS represent a new approach to gene delivery and localized therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724671     DOI: 10.1038/sj.gt.3302214

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

Review 1.  Polymeric nucleic acid carriers: current issues and novel design approaches.

Authors:  Han Chang Kang; Kang Moo Huh; You Han Bae
Journal:  J Control Release       Date:  2012-07-04       Impact factor: 9.776

Review 2.  Design of modular non-viral gene therapy vectors.

Authors:  Laura De Laporte; Jennifer Cruz Rea; Lonnie D Shea
Journal:  Biomaterials       Date:  2005-10-21       Impact factor: 12.479

Review 3.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

4.  Synthesis and structure-activity relationships of novel cationic lipids with anti-inflammatory and antimicrobial activities.

Authors:  Melissa Myint; Robert Bucki; Paul A Janmey; Scott L Diamond
Journal:  Bioorg Med Chem Lett       Date:  2015-05-11       Impact factor: 2.823

5.  Glucocorticoid Cell Priming Enhances Transfection Outcomes in Adult Human Mesenchymal Stem Cells.

Authors:  Abby M Kelly; Sarah A Plautz; Janos Zempleni; Angela K Pannier
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

6.  Development of a successive targeting liposome with multi-ligand for efficient targeting gene delivery.

Authors:  Kun Ma; Haijun Shen; Song Shen; Men Xie; Chuanbin Mao; Liyan Qiu; Yi Jin
Journal:  J Gene Med       Date:  2011-05       Impact factor: 4.565

7.  Novel cationic lipids with enhanced gene delivery and antimicrobial activity.

Authors:  David E Fein; Robert Bucki; Fitzroy Byfield; Katarzyna Leszczynska; Paul A Janmey; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-06-23       Impact factor: 4.436

8.  TLR9 and IRF3 cooperate to induce a systemic inflammatory response in mice injected with liposome:DNA.

Authors:  Wendy E Walker; Carmen J Booth; Daniel R Goldstein
Journal:  Mol Ther       Date:  2010-02-09       Impact factor: 11.454

9.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

10.  Cationic lipid formulations alter the in vivo tropism of AAV2/9 vector in lung.

Authors:  David E Fein; Maria P Limberis; Sean F Maloney; Jack M Heath; James M Wilson; Scott L Diamond
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.